We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Oscient Pharmaceuticals Corporation has granted the commercialization rights to FACTIVE (gemifloxacin mesylate) tablets in Canada to Abbott Canada, the Canadian affiliate of Abbott.
Drug maker Cephalon Inc. said it will end development of a troubled attention deficit disorder treatment after receiving notification from the Food and Drug Administration that it could not approve the drug.
The New England Journal of Medicine released results of a six-year clinical trial finding the drug Lipitor, given in high doses to stroke patients who had no heart disease, was effective in preventing a second stroke.
ConjuChem Biotechnologies has posted the findings of its investigation into the recent death of a patient in its Phase II trial of DAC:GRF in HIV lipodystrophy, an event that caused the company to halt the trial and, subsequently, lose half the value of its stock.
Barr Pharmaceuticals, Inc. announced that the Croatian Financial Services Supervisory Agency (HANFA) has approved for publication its tender offer for the purchase of 100% of the shares of PLIVA d.d., based in Zagreb, Croatia.
Threshold Pharmaceuticals, Inc., reported financial results for the second quarter ended June 30, 2006, a corporate realignment to focus on programs for multiple potential cancer indications and adoption of a shareholder rights plan.
The FDA sent a warning letter to Elizabeth Hohmann of Massachusetts General Hospital in Boston for studies of vaccines for listeria and salmonella for which she served as sponsor and clinical investigator.
The FDA has formed an internal Nanotechnology Task Force to help the agency further understand this emerging science and determine how to regulate as well as encourage the development of products that use it.